Global Anti-Viral Drugs Market Size, Forecast and Trend Highlights Over 2022 – 2031

The global anti-viral drugs market is estimated to garner notable revenue by the end of 2031 by growing at a modest CAGR of ~5% over the forecast period, i.e., 2022 – 2031. Further, the market generated a revenue of ~USD 55.0 Billion in the year 2021. The growth of the market can primarily be attributed to the rising global occurrences of HIV infection. According to the World Health Organization (WHO), approximately 79.3 million people were suffering from the HIV virus and caused nearly 37.7 million deaths at the end of 2021.

Get more information on this report: Request Sample PDF

Anti-viral drugs are used to treat viral infections such as human immunodeficiency virus (HIV), hepatitis, herpes, coronavirus, and influenza. On the other hand, there are some side effects of anti-viral drugs such as appetite loss, diarrhoea, and fatigue on patients when used for medication. However, this cannot rule out the benefits provided by them to patients dealing with severe infections and viruses. The ongoing influenza flu cases are anticipated to propel the market growth during the forecast period. As per the statistics by the Centers for Disease Control and Prevention in 2021, in the U.S.A, total, 1,899 (0.2%) of 1,081,671 samples tested for influenza viruses tested positive (713 (7.5%) for influenza A and 1,186 (7.5%) for influenza B. In that same period, 61.4% of influenza positive samples originated from influenza A, and 38.6% originated from influenza B.  

Global Anti–Viral Drugs Market: Growth Drivers and Challenges

Growth Drivers

• Surge in Herpes Cases – Herpes infection is a common infection that is caused by the herpes simplex virus (HSV) and treated with the antiviral drugs medication. Therefore, it is expected to surge the growth of the global anti-viral drugs market.

For instance in 2022, globally, nearly 3.7 billion people under the age of 50 (67%) are suffering from HSV-1 infection, whereas 491 million people aged between 15–49 (13%) have HSV-2 infection.

• Growing Prevalence of hepatitis B infection – Approximately 296 million people were living with chronic hepatitis B infection in 2019, resulting in an estimated 820,000 deaths. Moreover, this figure is growing each year, with 1.5 million new infection cases.
• Increase in Sexually Transmitted Infections (STIs) –

Every day more than 1 million cases of sexually transmitted infections (STIs) are reported globally.

• Rising Occurrences of Respiratory Syncytial virus (RSV) Globally – According to the Centers for Disease Control and Prevention, more than 57,000 hospitalizations, 1.5 million outpatient clinic visits, and 500,000 emergency department visits of children less than the age of 5 years owing to RSV in the United States every year

Challenges

• Increasing Cases of Prescription Drug Abuse
• Rising Awareness About Alternative Treatments
• High Cost of Drugs Used to Treat Viral Infections, Such as Hepatitis

The global anti-viral drugs market is segmented and analyzed for demand and supply by indication into hepatitis, herpes, HIV AIDS, influenza, coronavirus, and others. Out of these, the coronavirus segment is expected to grow at a rapid pace in the forecast period on the back of the globally increasing rate of the COVID-19 cases, which contributed to the enormous growth of this segment. The sudden outbreak of COVID-19 cases and the main focus of healthcare facilities on the treatment of COVID-19 patients has boosted the market growth of anti-viral drugs. As a result, various pharmaceutical companies have been focusing on new drug development for effective treatment and better recovery of COVID-19 patients. For instance, globally there are 568,773,510 confirmed cases of COVID-19 accounting for 6,381, 643 deaths on 26 July 2022.

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Anti-Viral Drug Market Regional Synopsis

Regionally, the global anti-viral drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa region. The market in the North America region is estimated to witness noteworthy growth over the forecast period on the back of the rising spending by the pharmaceutical industry for research and development, ongoing clinical trials, and growing approvals for the drugs in the region. The United States pharmaceutical industry’s spending on research and development has increased from 17.4 per cent of the total revenues in 2010 to 21.4 per cent of the total revenues in 2020.   

The anti-viral drugs market size in Europe is also estimated to gain notable growth over the forecast period, owing to the rise in the patient pool of various infectious diseases and growth in the healthcare infrastructure. As per the data released by the European Centre for Disease Prevention and Control, the rising outbreak of monkeypox cases has been affecting the United Kingdom (UK), the EU/EEA, Asia, the Americas, and Australia. Around 9,697 cases of monkeypox have been reported from 27 countries throughout the European region.

The global anti-viral drugs market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook
• The Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of the Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global anti-viral drugs market includes the following segments:

Top Featured Companies Dominating the Global Anti-Viral Drugs Market

• GlaxoSmithKline Plc

• Company Overview
• Business Strategy
• Key Product Offerings
• Financial Performance
• Key Performance Indicators
• Risk Analysis
• Recent Development
• Regional Presence
• SWOT Analysis

• AbbVie Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Cipla Inc.
• Aurobindo Pharma Limited
• Gilead Sciences, Inc.
• F. Hoffmann-La Roche Ltd.
• Bristol-Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.